Acacia Pharma
Acacia Pharma was a Cambridge company that repurposed the old antipsychotic amisulpride, at low dose, to prevent and treat nausea and vomiting after surgery and chemotherapy; it was bought by Eagle Pharmaceuticals in 2022.
Overview
Acacia Pharma, founded in 2007 in Cambridge, England, developed intravenous low-dose amisulpride (Barhemsys) for postoperative nausea and vomiting, approved by the FDA in 2020, and tested the same drug (APD403) in phase 3 for chemotherapy-induced nausea and vomiting. Eagle Pharmaceuticals acquired the company in 2022. Its trials remain on ClinicalTrials.gov under Acacia as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.